The alpha emitter Radium-223 (223Ra-Cl2) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone refractory prostate cancer.
More than 1,000 patients have been included in clinical phase I-III tests showing significant reduction in alkaline phosphatase- and PSA level and prolonged survival. Adverse events are usually mild to moderate and comprise gastrointestinal and myelotoxic symp-toms. Intravenously administered 223Ra-Cl2 (half-life 11.4 days) will likely be given every four weeks for six treatments to out-patients.
Written by:
Mortensen J, Højgaard L. Are you the author?
Klinik for Klinisk Fysiologi, Nuklearmedicin & PET, Rigshospitalet, Blegdamsvej 9, 2100 København Ø.
Reference: Ugeskr Laeger. 2014 Jul 21;176(30). pii: V04130224.
PubMed Abstract
PMID: 25292232
Article in Danish.